Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.
Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells.
Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.